EUVIMEDEUVIMED entdecken
Multizentrische StudieBeobachtungsstudie

Treatment with fostamatinib in patients with immune thrombocytopenia: Experience from the Andalusian region in Spain—The Fostasur Study

Reyes Jiménez-Bárcenas, Gloria García-Donas-Gabaldón, Rosa María Campos-Álvarez, María Carmen Fernández-Sánchez de Mora, Josefa Luis-Navarro, Juan Francisco Domínguez-Rodríguez, María Del Mar Nieto-Hernández, Irene Sánchez-Bazán, Maria Yera-Cobo, Rocio Cardesa-Cabrera, Francisco José Jiménez-Gonzalo, María Antonia Ruiz-Cobo und 10 weitere

British Journal of Haematology · 2024-05 · 204 (5) · 1977-1985

DOI: 10.1111/bjh.19443 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift British Journal of Haematology, online erschienen am 03.04.2024. Verfasst von Reyes Jiménez-Bárcenas und 21 weiteren Autor:innen. Beteiligte Einrichtung: Hospital de la Serranía de Ronda, Málaga, Spain. Hauptthemen laut MEDLINE: Purpura, Thrombocytopenic, Idiopathic, Aminopyridines, Morpholines, Pyridines. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 18 Literaturangaben. Gefördert von: Grifols.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Immune thrombocytopenia (ITP) is characterized by low platelet counts (PLTs) and an increased risk of bleeding. Fostamatinib, a spleen tyrosine kinase inhibitor, has been approved as a second‐line treatment for ITP. Real‐world data on fostamatinib are lacking. This observational, retrospective, multicentre study, conducted in the Andalusia region of Spain, evaluated 44 adult primary ITP patients (47.7% female; median age 58 years; newly diagnosed ITP 6.8%; persistent 13.6%; chronic 79.5%; median four prior treatments) after ≥ 4 weeks of fostamatinib therapy. The median PLT at the initiation of fostamatinib was 15 × 10 9 /L. Common reasons for starting fostamatinib were refractoriness or intolerance to prior therapy, oral medication preference, history of thrombosis and cardiovascular risk. Dosing was individualized based on efficacy and tolerance. After 2 weeks, global response rate was 56.8% (response and complete response). Response rates were 70.5%, 62.5% and 64% at 4 weeks, 12 weeks and at the end of the study respectively. Adverse events were mild, and no patients discontinued as a result. This real‐world study demonstrated a response rate similar to fostamatinib as seen in the pivotal clinical trials while including newly diagnosed patients and allowing for individualized dosing.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Purpura, Thrombocytopenic, IdiopathicAminopyridinesMorpholinesPyridinesHumansMiddle AgedFemaleMaleSpainAgedRetrospective StudiesAdultOxazinesPyrimidinesTreatment OutcomeProtein Kinase InhibitorsAged, 80 and over

Stichwörter der Autor:innen

ITPplatelet immunologyplateletsthrombocytopenia

Substanzen

fostamatinibAminopyridinesMorpholinesPyridinesOxazinesPyrimidinesProtein Kinase Inhibitors

Autor:innen und Institutionen

  • Hospital de la Serranía de Ronda, Málaga, Spain.
  • Hospital Universitario Virgen Macarena, Sevilla, Spain.
  • Hospital Universitario de Jerez de la Frontera, Cádiz, Spain.
  • Hospital Universitario Reina Sofía, Córdoba, Spain.
  • Hospital de Riotinto, Huelva, Spain.
  • Hospital Universitario Juan Ramón Jiménez, Huelva, Spain.

ORCID-Profile: María Eva Mingot-Castellano

Förderung

  • Grifols

Zitieren

APA

Jiménez-Bárcenas, R., García-Donas-Gabaldón, G., Campos-Álvarez, R. M., Fernández-Sánchez de Mora, M. C., Luis-Navarro, J., Domínguez-Rodríguez, J. F., Nieto-Hernández, M. D. M., Sánchez-Bazán, I., Yera-Cobo, M., Cardesa-Cabrera, R., Jiménez-Gonzalo, F. J., Ruiz-Cobo, M. A., Caparrós-Miranda, I., Entrena-Ureña, L., Fernández Jiménez, D., Díaz-Canales, D., Moreno-Carrasco, G., Calderón-Cabrera, C., Núñez-Vázquez, R. J., …, & Grupo Andaluz de Coagulopatías (GACC) (2024). Treatment with fostamatinib in patients with immune thrombocytopenia: Experience from the Andalusian region in Spain—The Fostasur Study. British Journal of Haematology, 204(5), 1977-1985. https://doi.org/10.1111/bjh.19443

Vancouver

Jiménez-Bárcenas R, García-Donas-Gabaldón G, Campos-Álvarez RM, Fernández-Sánchez de Mora MC, Luis-Navarro J, Domínguez-Rodríguez JF, et al. Treatment with fostamatinib in patients with immune thrombocytopenia: Experience from the Andalusian region in Spain—The Fostasur Study. British Journal of Haematology. 2024;204(5):1977-1985. doi:10.1111/bjh.19443

BibTeX
@article{JimnezBrcenas2024,
  author = {Jiménez-Bárcenas, Reyes and García-Donas-Gabaldón, Gloria and Campos-Álvarez, Rosa María and Fernández-Sánchez de Mora, María Carmen and Luis-Navarro, Josefa and Domínguez-Rodríguez, Juan Francisco and Nieto-Hernández, María Del Mar and Sánchez-Bazán, Irene and Yera-Cobo, Maria and Cardesa-Cabrera, Rocio and Jiménez-Gonzalo, Francisco José and Ruiz-Cobo, María Antonia and Caparrós-Miranda, Isabel and Entrena-Ureña, Laura and Fernández Jiménez, Dolores and Díaz-Canales, Dana and Moreno-Carrasco, Gloria and Calderón-Cabrera, Cristina and Núñez-Vázquez, Ramiro José and Pedrote-Amador, Begoña and Mingot-Castellano, María Eva and Grupo Andaluz de Coagulopatías (GACC), Grupo Andaluz de Coagulopatías (GACC)},
  title = {Treatment with fostamatinib in patients with immune thrombocytopenia: Experience from the Andalusian region in Spain—The Fostasur Study},
  journal = {British Journal of Haematology},
  year = {2024},
  volume = {204},
  number = {5},
  pages = {1977--1985},
  doi = {10.1111/bjh.19443}
}
Kostenlos starten →